Trial Profile

A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Capecitabine; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms LOGiC
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; Novartis; Novartis Pharmaceuticals

Most Recent Events

30 Oct 2024 Status changed from active, no longer recruiting to completed.
27 Sep 2024 Planned End Date changed from 22 Jan 2025 to 3 Oct 2024.
31 May 2024 Planned End Date changed from 22 Aug 2024 to 22 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com